【英語タイトル】Global Sjogren’s Syndrome Market - 2023-2030
	・商品コード：DTM23FB27 ・発行会社（調査会社）：DataM Intelligence ・発行日：2023年1月 ・ページ数：200 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：医療

Sjögren’s Syndrome Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).

The two most typical symptoms of Sjogren’s syndrome (SS), an immune system illness, are dry eyes and a dry mouth. The syndrome frequently coexists with other immune system diseases like lupus and rheumatoid arthritis. The mucosal membranes and moisture-secreting glands of the mouth and eyes are typically impacted first in Sjogren’s syndrome, which causes less saliva and tears to be produced. In women, the illness is far more prevalent. The goal of treatment is to diminish symptoms.

Market Dynamics

The major factors driving the global sjogren’s syndrome market are that Sjogren’s syndrome and other autoimmune illnesses are becoming more common, increasing awareness and the need for cutting-edge medical care, additionally, a strong drug pipeline has contributed to the market’s expansion

Sjogren’s syndrome and other autoimmune illnesses are becoming more common and are expected to drive the market’s growth.

The primary symptoms of Sjogren syndrome (SS) are dry mouth and eyes. The illness can happen at any age, but it often starts to worsen progressively in middle adulthood. Sjogren syndrome is one of a vast set of ailments known as autoimmune disorders that take place when the immune system targets the body’s own tissues and organs. In Sjogren syndrome, the immune system predominantly targets the salivary glands and the lacrimal glands, which limit the glands’ capacity to secrete tears and saliva. The incidence of Sjogren syndrome is close to half that of rheumatoid arthritis (RA), or it affects 0.5% to 1.0% of the population, according to

The National Centre for Biotechnology Information 2022. Sjogren’s syndrome affects between 400,000 and 3.1 million adult people. Although this illness can affect individuals of any age, the average onset of symptoms is between the ages of 45 and 55. Rheumatoid arthritis and other connective tissue illnesses, such lupus, are also present in about half of patients.

Sjogren has been recorded in adults and children less frequently throughout the world, and there doesn’t seem to be any racial or geographic bias in incidence. However, the disorder has a clear preference for females, and similar to SLE, the female: male ratio is around 9:1. The condition typically manifests in middle age, but it can also affect young children and the elderly.

Lack of knowledge regarding the availability of the Sjogren’s syndrome drug is expected to hamper the market’s growth.

However, the high cost of treatment and sjogren’s disease consequences such acute dehydration, rapid weight loss, and inflammation will restrain market expansion. During the aforementioned projection period, the sjogren’s syndrome market will face challenges from a lack of knowledge regarding the condition, its preventative measures, and drug side effects.

COVID-19 Impact Analysis

During the Pandamic, most industries experienced negative repercussions. This can be attributed to significant disruptions in their manufacturing and supply chains as a result of various preventative lockdowns and other limitations imposed by international regulatory organizations. The market is the same. The general economic status of the majority of people has been severely hit by the pandamic, which has also resulted in a fall in consumer demand as people are more inclined to eliminate non-essential expenditure from their budgets. During the projected period, it is anticipated that the aforementioned factors will have a negative impact on the market.

There is also a resurgence of interest in enhancing the resilience of diversified supply chains to provide reliable access to vital raw materials. Due to the urgent need to approve new COVID-19 vaccines and therapies, regulatory agencies have simplified the evaluation and approval processes. It is hoped that these advancements will increase the clinical and commercial success of future medicines. However, it is projected that the worldwide Sjogren syndrome (SS) industry will recover once the relevant governing authorities start pharmaceuticals lift such imposed lockdowns.

Segment Analysis

The hospital’s segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Hospitalization rates were greater for SS patients than for the general population. Patients with SS were more likely than comparators to be hospitalized for endocrine/metabolic illnesses, cardiovascular diseases, musculoskeletal diseases, connective tissue disorders, and traumas. People with Sjogren’s disease are more likely to need inpatient hospital care for infections picked up in the community, especially those of the lungs and intestines, according to Sjogren’s syndrome News from October 2022. Hospitalizations for opportunistic infections, such as mycobacterium infections and the chickenpox/shingles virus (zoster), are also more common in this patient population. Sjogren’s patients had a 98% higher overall hospitalization rate for a first infection than healthy individuals did.

According to experts from the University of Montpellier in France, while the effect of infections on outcomes related to other autoimmune illnesses has been extensively discussed, little is known regarding the prevalence of severe infections necessitating hospitalization in Sjogren’s patients.

Geographical Analysis

North America holds the largest market share in the global Sjogren’s Syndrome market.

North America dominates the global Sjogren’s syndrome market primarily due to its large population, excellent medical infrastructure, and high-income levels. Around 1 in 200 Americans are thought to be affected by Sjogren’s syndrome, according to the Johns Hopkins Sjogren’s Center 2021. A team of knowledgeable professionals must evaluate patients who believe they may have Sjogren’s syndrome. The doctors at the Jerome Greene Sjogren’s syndrome Center at Johns Hopkins have great experience in Sjogren’s syndrome diagnosis, treatment, and research. Their knowledge is currently centralized in a facility easily accessible on the Johns Hopkins Bayview campus in Baltimore, Maryland. Rheumatologists, ophthalmologists, neurologists, and gynecologists make up the company team and review 200–300 new patients with a suspected or confirmed diagnosis of Sjogren’s syndrome each year.

Additionally, many businesses are there, and the syndrome that propels the region is developing. For instance, in September 20222, advancement prospects increase once Novartis completes a Phase II Sjogren’s syndrome trial. The team at Clinical Trials Arena also looks at a leishmaniasis trial suspension, a lymphoma trial termination, and trial completions for endometriosis and dry eye syndrome. Remibrutinib (LOU-064) from Novartis saw an increase in its Phase Transition Success Rate (PTSR) of eight points to 34% in Sjogren’s syndrome following the conclusion of Phase II research.

Competitive Landscape

The sjogren’s syndrome market is moderately competitive with local and global companies’ presence. Novartis AG, Allergan Inc, Otsuka Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd., Nicox S.A, Argentis Pharmaceuticals, LLC, Auven Therapeutics, Abbvie Inc Cellzome GmbH, Biogen Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in November 2022, For those with autoimmune and chronic inflammatory disorders, including Sjogren’s syndrome, Motto Health has opened a kind of virtual clinic with rheumatologists and medical specialists, the startup revealed. The technology enables patients to manage and track symptoms, schedule virtual consultations with physicians, and obtain individualized treatment regimens using an online application.

Novartis AG.

Overview: A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. Among other things, it offers medicines for the treatment of infections, cancer, cardiovascular disease, dermatological issues, neurological disorders, ophthalmic and respiratory illnesses, and cancer. Through Sandoz, the business provides biosimilars and generic medications. Through The Novartis Institutes for BioMedical Research, Novartis carries out research in a number of illness areas (NIBR).

Product Portfolio

Hydroxychloroquine (Plaquenil): The anti-rheumatic medicine hydroxychloroquine (Plaquenil) is a disease-modifying medication (DMARD). It can lessen arthritic pain and swelling. It might stop joint deterioration and lessen the possibility of permanent impairment. The drug hydroxychloroquine belongs to a group of drugs that were initially used to treat and prevent malaria.

Key Development: In September 2022, Sjogren’s syndrome Phase II trial by Novartis is now complete. After that, they suspend the Phase I study for visceral leishmaniasis, end the Phase I trial for B-cell lymphoma, and complete the Phase I trials for endometriosis and dry eye syndrome.

The global Sjogren’s Syndrome market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.